Trial Profile
Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 6-way Cross-over Study to Evaluate the Abuse Potential of Single, Oral Doses of ACT-541468 in Healthy Recreational Drug Users
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Daridorexant (Primary) ; Suvorexant; Zolpidem
- Indications Insomnia
- Focus Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 14 Mar 2022 Primary endpoint (Maximum effect (Emax) of the Drug Liking VAS (at this moment) over 24 h post-dose during each treatment period) has been met according to the results published in the Sleep
- 14 Mar 2022 Results published in the Sleep
- 15 Sep 2020 Results presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology